The much-debated prostate-specific antigen (PSA) test used to assess patients’ risk of prostate cancer is receiving a big formal thumbs down from one major national organization, who views the test as highly inaccurate and susceptible to overdiagnosis. Current Problems A new study from the Canadian Task Force on Preventive Health Care argues PSA tests present patients…
This post was imported from a legacy archive. Please excuse any formatting inconsistencies.